Title Page

Running Title: Clinical Characteristics of COVID-19 Clinical Characteristics of Children with COVID-19: A Rapid Review and Meta-Analysis

Zijun Wang^{1*}, Qi Zhou^{2*}, Chenglin Wang^{3*}, Qianling Shi², Shuya Lu^{4,5}, Yanfang Ma¹, Xufei Luo⁹, Yangqin Xun¹, Weiguo Li^{7,8,9}, Muna Baskota³, Yinmei Yang³, Hui Zhai³, Toshio Fukuoka^{10,11}, Hyeong Sik Ahn^{12,13}, Myeong Soo Lee^{14,15}, Zhengxiu Luo^{7,8,9}, Enmei Liu^{7,8,9#}, Yaolong Chen^{1,16,17,18#}; on behalf of COVID-19 evidence and recommendations working group

- Evidence-based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China
- 2. The First School of Clinical Medicine, Lanzhou University, Lanzhou 730000, China
- 3. Children's Hospital of Chongqing Medical University, Chongqing 400014, China
- 4. Department of Pediatric, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu 611731, China.
- 5. Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu 610072, China.
- 6. School of Public Health, Lanzhou University, Lanzhou 730000, China
- 7. Department of Respiratory Medicine, Children's Hospital of Chongqing Medical University, Chongqing 400014, China
- 8. National Clinical Research Center for Child Health and Diseases, Ministry of Education Key Laboratory of Child Development and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Children's Hospital of Chongqing Medical University, Chongqing 400014, China
- 9. Chongqing Key Laboratory of Pediatrics, Chongqing 400014, China
- 10. Emergency and Critical Care Center, the Department of General Medicine, Department of Research and Medical Education at Kurashiki Central Hospital, Japan
- 11. Advisory Committee in Cochrane Japan, Japan
- 12. Department of Preventive Medicine, Korea University College of Medicine, Seoul, Korea
- 13. Korea Cochrane Centre, Korea
- 14. Korea Institute of Oriental Medicine, Daejeon, Korea
- 15. University of Science and Technology, Daejeon, Korea
- 16. Lanzhou University, an Affiliate of the Cochrane China Network, Lanzhou 730000, China
- 17. Chinese GRADE Center, Lanzhou 730000, China
- 18. Key Laboratory of Evidence Based Medicine and Knowledge Translation of Gansu Province, Lanzhou University, Lanzhou 730000, China

Correspondence to: Enmei Liu. Department of Respiratory Medicine, Children's Hospital of Chongqing Medical University, Chongqing 400014, China. Email: emliu186@126.com; Yaolong Chen. Evidencebased Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China. Email: chenyaolong@lzu.edu.cn.

^{*} These authors contributed equally to this work.

Abstract

Background: Most guidelines on COVID-19 published so far include recommendations for

patients regardless of age. Clinicians need a more accurate understanding of the clinical

characteristics of children with COVID-19.

Methods: We searched studies reporting clinical characteristics in children with COVID-19

published until March 31, 2020. We screened the literature, extracted the data and evaluated the

risk of bias and quality of evidence of the included studies. We combined some of the outcomes

(symptoms) in a single-arm meta-analysis using a random-effects model.

Results: Our search retrieved 49 studies, including 25 case reports, 23 case series and one cohort

study, with a total of 1667 patients. Our meta-analysis showed that most children with COVID-

19 have mild symptoms. Eighty-three percent of the children were within family clusters of cases,

and 19% had no symptoms. At least 7% with digestive symptoms. The main symptoms of children

were fever (48%, 95% confidence interval [CI]: 39%, 56%) and cough (39%, 95% CI: 30%, 48%).

The lymphocyte count was below normal level in only 15% [95% CI: 8%, 22%] of children which

is different from adult patients. 66% [95% CI: 55%, 77%] of children had abnormal findings in

CT imaging.

Conclusions: Most children with COVID-19 have only mild symptoms, and many children are

asymptomatic. Fever and cough are the most common symptoms in children. Vomiting and

diarrhea were not common in children. The lymphocyte count is usually within the normal range

in children.

Keywords: Children; clinical characteristics; COVID-19; meta-analysis; rapid review.

Background

In December 2019, a previously unknown type of pneumonia broke out in Wuhan, China, which was later confirmed to be caused by a novel type of beta coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). In February 2020, the World Health Organization (WHO) officially named the disease as "Coronavirus Disease 2019 (COVID-19)" (1). Like MERS-CoV and SARS-CoV, SARS-CoV-2 can also be transmitted between humans (2-5). Since the first occurrence of COVID-19 case in Wuhan, Hubei Province, China on December 8, 2019 (6, 7), the disease is spreading rapidly. WHO reassessed the potential impact of COVID-19 on global public health and subsequently declared COVID-19 as Public Health Emergency of International Concern (PHEIC) on January 30, 2020.

Research has proven that people of all ages are susceptible to SARS-CoV-2. The mean age of COVID-19 patients was 47 years, with 55% of the patients being between 15 and 49 years old. Only 9% of the patients were under 15 years old. (8) For this reason, most of the guidelines published so far include recommendations for patients regardless of age, only a few recommendations are for children. Although the great majority of patients are adults, children's respiratory structural characteristics and immune response system differ essentially from those in adult (9-11), and the diagnostic criteria and management according to recommendations targeting adults may not be appropriate for children. Our study aims therefore to identify the clinical features of children with COVID-19, help clinicians to confirm and treat the suspected children as soon as possible, and provide support for the development of guidelines for COVID-19 in children.

Methods

Search strategy

We comprehensively searched the following electronic databases: Cochrane library, MEDLINE (via PubMed), Embase, Web of Science, China Biology Medicine disc (CBM), China National Knowledge Infrastructure (CNKI), and Wanfang Data from their inception until March 31, 2020 with the terms "2019-novel coronavirus", "SARS-CoV-2", "COVID-19", "2019-nCoV", "clinical features" and their derivatives. We also searched World Health Organization (WHO), Chinese Center for Disease Control and Prevention (CCDC), National Health Commission of the People's Republic of China, USA National Institutes of Health Ongoing Trials Register (ClinicalTrials.gov), the **ISRCTN** Google Scholar registry, and the preprint servers medRxiv (https://www.medrxiv.org/), bioRxiv (https://www.biorxiv.org/) and **SSRN** (https://www.ssrn.com/index.cfm/en/). In addition, we searched the reference lists of the identified studies for further potential studies. The full search strategy can be found in Supplementary Material 1.

Inclusion and exclusion criteria

We included studies on children (aged <18 years) with COVID-19 that report clinical features of patients, such as symptoms, signs, laboratory examinations and imaging manifestations. Diagnosis of COVID-19 was based on the Novel Coronavirus Pneumonia Prevention and Control Program (7th edition) issued by the National Health and Health Committee of China (12) and surveillance case definitions for human infection with novel coronavirus (nCoV) Interim guidance v2 issued by World Health Organization (13). We excluded in vitro studies, Traditional Chinese Medicine studies, conference abstracts, comments, letters, and duplicates, and studies where we could not extract the data. We made no restrictions on language and publication status.

Study selection

Two reviewers (Z Wang and C Wang) selected the studies independently after first eliminating duplicates. The bibliographic software EndNote was used and any discrepancies were settled by discussion, consulting a third reviewer (Q Zhou) if necessary. Before the formal selection, the reviewers searched a random sample of 50 citations. The reviewers screened first all titles and abstracts with the pre-defined criteria, and categorized the articles into three (eligible, not eligible, and unclear) groups. In the second Step, full-texts of those potentially eligible or unclear studies were reviewed to identify the final inclusion. All the reasons for exclusion of ineligible studies were recorded, and the process of study selection was documented using a PRISMA flow diagram (14, 15).

Data extraction

Two reviewers (Q Shi and S Lu) extracted the data independently with a standardized data collection form, including:1) basic information (e.g. first author); 2) symptoms; 3) routine blood tests (e.g. leucocyte count); 4) blood biochemistry (e.g. alanine aminotransferase); 5) coagulation function (e.g. activated partial thromboplastin time); 6) imaging findings (e.g. abnormal imaging). For dichotomous outcomes, we abstracted the number of events and total participants per group. For continuous outcomes, we abstracted means, standard deviations (SD), and the number of total participants in per group. Outcomes with no events were reported, but these were excluded from the meta-analysis. If means and standard deviations (SD) were not reported, we calculated them from the reported indicators. (16) If data were missing or reported in an unusable way, we excluded the study from the meta-analysis and report the findings descriptively.

Risk of bias assessment

Two reviewers (Z Wang and C Wang) assess the risk of bias in each study independently. Discrepancies were settled by discussion, consulting a third reviewer (Q Zhou) if necessary. For randomized controlled trials (RCTs), we will assess the risk of bias independently using Cochrane risk-of-bias tool (17). It consists of seven domains, for each, we will grade as "Low", "Unclear", and "High". For nonrandomized controlled trials (nRCTs), ROBINS-I tool will be used(18). It consists of seven domains, for each, we will grade as "Low risk", "Moderate risk", "Serious risk", "Critical risk", and "No information". For case-control and cohort studies, the Newcastle-Ottawa Scale will be used (19, 20). It consists of eight domains, for each, we will grade with stars. The more stars, the lower the risk of bias. For cross-sectional studies, we use a methodology evaluation tool recommended by Agency for Healthcare Research and Quality (AHRQ) (21). This tool assesses the quality of bias according to 11 criteria. And each criterion is answered by "Yes", "No" or "unsure". For case reports and case series, we used a methodology evaluation tool recommended by National Institute for Health and Care Excellence (NICE) (22). The risk of bias is evaluated according to eight criteria. The results were summarized by scoring method, for the "Yes" items, the score was 1, and for the "no" items, the score was 0. The higher the total score, the lower the risk of bias.

Data synthesis

We summarized the results of the studies including less than 9 patients and did meta-analysis of included studies that have at least 9 patients. For dichotomous outcomes, we did a meta-analysis of proportions, reporting the effect size (ES) with 95% confidence intervals (CI). For continuous outcomes, we did a meta-analysis of continuous variable, calculating the effect size (ES) with 95% CI. We described the results of the studies with patients that below nine. As clinical and methodological heterogeneity in the study design,

characteristics of participants, interventions and outcome measures was expected, we used random-effects models (23). Two-sided P values < 0.05 were considered statistically significant. Heterogeneity was defined as P values <0.10 and I^2 >50%. All analyses were performed in STATA version 14.

Quality of the evidence assessment

Two reviewers (Q Zhou and Y Xun) assessed the quality of main evidence independently using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) tool. We produced a "Summary of Findings" table using the GRADE pro software (24, 25). Direct evidence from RCTs is first set as high quality, and evidence from observational studies as low quality. Then initial quality can then be downgraded for five reasons (study limitations, consistency of effect, imprecision, indirectness, and publication bias) and upgraded for three reasons (large magnitude of effect, dose-response relation and plausible confounders or biases) (26-31). Finally, the quality of main evidence can be classified as high, moderate, low, or very low, which reflects the extent to what we can be confident that the effect estimates are correct.

As COVID-19 is a public health emergency of international concern and the situation is evolving rapidly, our study was not registered in order to speed up the process. (32)

Results

Study selection and characteristics

Our initial search retrieved 774 records (*Figure 1*). After removing duplicates, we screened the titles, abstracts and full texts, and 49 studies were finally included. The articles included 25 case reports, 23 case series and one cohort study. The studies included a total of 1667 patients: 955 males and 712 females. Eighteen percent of children were aged less than one year. Most of the studies were carried out in China, including 17 studies

from Hubei (*Table 1*). One study was from Singapore, one from Korea, one from Vietnam and one from Iran. The results on risk of bias are reported in *Supplementary Material 2*, and quality of the evidence in *Supplementary Material 3*.

Symptoms and imaging results

All of the included studies reported the symptoms of children with COVID-19. The results showed that 83% [95% CI: 78%, 88%] of the cases had likely acquired the infection from their family members with COVID-19. 94% [95% CI: 90%, 98%] of children were mild cases and 3% [95% CI: 2%, 4%] were severe case. Among the children with severe symptoms that reported symptom clearly, 9 children have comorbidity, 10 children have gastrointestinal symptoms and 4 children have concurrent infection. Only two children were dead that has been reported in our included studies.(47, 66) The main symptoms were fever (48% [95% CI: 39%, 56%]), cough (39% [95% CI: 30%, 48%]). Thirty percent [95% CI: 18%, 42%] of children had both cough and fever. 7% [95% CI: 5%, 9%] and 6% [95% CI: 4%, 9%] of cases had diarrhea and nausea/vomiting. The proportion of children with more than one symptom was 35% [95% CI: 21%, 48%], and 19% [95% CI: 14%, 23%] of all children were asymptomatic.

Forty-two studies reported the imaging features of children with COVID-19, including 19 case series and 23 case reports. 66% [95% CI: 55%, 77%] had abnormal imaging. 35% [95% CI: 26%, 44%] of children had ground-glass opacity.

More information can be found in *Table 2* and *Supplementary Material 4*.

Laboratory results

Seventeen case series reported the results of routine blood tests. The mean leucocyte count in children was 6.25×10^9 /L [95% CI: 5.97, 6.54]. 15% [95% CI: 4%, 26%] of cases had leucocyte count above the normal range and 28% [95% CI: 17%, 38%] of cases below

the normal range. The mean lymphocyte count in children was 2.84×10 9/L [95% CI: 2.55,

3.13]. Lymphocyte count was elevated in 41% [95%CI: 2%, 80%] and below normal in

15% [95% CI: 8%, 22%] of children.

Eighteen case series reported the results of blood biochemistry tests. The mean value of

alanine aminotransferase (ALT) was 20.46 U/L [95% CI: 14.51, 26.41], and 11% [95%

CI: 8%, 14%] of cases had elevated ALT values. The mean value of aspartate

aminotransferase (AST) was 32.04 U/L [95% CI: 30.25, 33.83], and 15% [95% CI: 9%,

21%] of cases had elevated AST values. The mean value of C-Reactive Protein (CRP)

was 5.05 mg/L [95% CI: 1.86, 8.24], and CRP was elevated in 22% [95% CI: 15%, 28%]

of the children.

Nine case series reported coagulation function test, the mean value of D-dimer was

0.33mg/L [95% CI: 0.17, 0.49] in studies of children with COVID-19. 15% [95% CI: 7%,

22%] of cases above the normal range of D-dimer value.

More information can be found in *Table 3* and *Supplementary Material 4*.

Discussion

Principal findings

Children had on average milder symptoms, with many children having even no symptoms.

Most children infected with COVID-19 were exposed through family clusters. About half

of children present with fever or cough, and about one third of children with both fever

and cough. Only a small minority of children had vomiting or diarrhea as initial symptoms.

Leucocyte and lymphocyte counts are often in normal or above the normal range in

children with COVID-19. Abnormalities in CT imaging were found in more than half of

the children, the most common being ground-glass opacity in unilateral lung.

The diagnosis of suspected cases in children needs comprehensive consideration. Fever and cough were the main symptoms in patients with COVID-19, which is reported by the most of current guidelines and recommendations. (12, 90-93) Although fever and cough

Attention should be paid to the children with COVID-19 who start with gastrointestinal symptoms. Although gastrointestinal symptoms such as nausea, vomiting and diarrhea are less common in children with COVID-19, recent studies have SARS-CoV-2 in the feces of patients (96, 97) and a study showed that some children persistently tested positive on rectal swabs even after nasopharyngeal testing was negative, raising the possibility of fecal—oral transmission.(98) According to one study, diarrhea was the first symptom in three out of 31 children.(88) Moreover, three of the eight children with severe cases of COVID-19 that reported symptom clearly had gastrointestinal symptoms, one of them started with gastrointestinal symptoms, without any obvious respiratory tract infection in the early stage (37). In addition, comorbidity cannot be ignored either. Our results showed that half of these eight children with severe cases had other diseases, including two with intussusception and one of them was dead (47). Similarly, a study of

Abnormal CT imaging was less common in children with COVID-19 than adults, but the imaging findings were similar in children and adults. Unilateral pneumonia is common in children with COVID-19, and the main change in imaging is ground-glass opacity. However, bilateral pneumonia is more common in adults, and the main change in imaging is also ground-glass opacity. (86, 87) One guideline (93) pointed out that there were multiple small patch shadows and interstitial changes in the early stages of the disease in adults, especially in the extrapulmonary zone in chest imaging. Furthermore, multiple ground-glass opacity or infiltrative shadows may develop in both lungs. In severe cases, pulmonary consolidation may occur, and pleural effusion is rare. An analysis of CT features in children with COVID-19 showed that in 15 cases, inflammatory infiltration was found in the chest CT imaging during initial diagnosis and reexamination. Most inflammatory infiltrations were manifested as small nodular ground-glass opacities, and multiple lobe segments were less involved. Multiple lobe segments were involved in only one case, and the imaging changes were not typical in the advanced stage as well (39). These findings suggest that pulmonary inflammation in children is mild and localized. The results of laboratory tests of children with COVID-19 were more often within the normal range than those of adults. The leukocyte count of children with COVID-19 was usually normal or below the normal range. The lymphocyte count was generally normal or above the normal range, and only 15% of cases were below the normal range. While

for adults, the leukocyte count was usually normal or above the normal range, and the lymphocyte count were mostly below the normal range (35%-63%).(86, 87) It can be seen that there were significant differences in routine blood values between adults and children. However, some published COVID-19 guidelines and consensus for children consider a reduction in lymphocyte count as one of the factors for diagnosing suspected cases (90-92). Our study demonstrates that guidelines for children should not be formulated in full

accordance with adult standards, otherwise true cases may be missed.

Most of the existing systematic reviews on characteristics of patients with COVID 10 or

Most of the existing systematic reviews on characteristics of patients with COVID-19 are based on adult patients or patients regardless of age.(100-105) Two of these compared the differences between children and adult patients.(100, 101) Only one review reported the clinical characteristics of children with COVID-19 at present.(106) All reviews that considered children had similar outcomes: for example, children had milder symptoms than adults, some children had no symptoms, and lymphopenia in children did not occur as often as in adults. But our rapid review has included 49 studies of children patients, which is more than most of these reviews together. In contrast to another systematic review of children with COVID-19 (106), we included studies not only China but also from other countries such as Singapore, which were published in Chinese and English. Moreover, we conducted a meta-analysis whereas the previous study only did a systematic literature review.

Strengths and limitations

This rapid review has several strengths. First, although this is not the first systemic review about the clinical characteristics of children with COVID-19, but is to our knowledge the first to combine the results with meta-analysis and GRADE evaluation of the quality of main evidence, which is of great importance for clinicians to diagnose and treat children

rapidly. Second, our study points out the loopholes in some current guidance documents

that suggest the diagnosis of suspected cases - also in children - based on the lymphocyte

count. Third, as a rapid review, this study summarizes the latest published information on

clinical cases, which provides relatively high-quality evidence for the formulation of

clinical practice guidelines in the rapidly evolving public health emergency situation and

helps policy-makers to make evidence-based decisions quickly (107).

Our study has also some limitations. First, due to the rapid fermentation of the public

health emergency and new cases emerging continuously, the findings of this review may

get outdates relatively soon. Second, cannot be sure if some cases were included in

multiple studies. Third, at present, there is no unified definition for clinical classification

of the severity of COVID-19, so we had to combine light, mild and moderate disease into

one category (mild), while severe and critical cases were both considered as severe cases.

Future implications

The researchers should aim to conduct more targeted studies on COVID-19 in specific

subpopulations. Policy makers should develop accurate guidelines for both children and

adults. Clinical practitioners should pay attention on the specific characteristics of

different patient populations to improve the accuracy of diagnosis and treatment.

Conclusion

Children with COVID-19 are more common to have only mild symptoms, and many

children are even completely asymptomatic. Fever and cough are the main symptoms of

COVID-19 in both children. Vomiting and diarrhea occurring less frequently in children.

Ground-glass opacity is the most common CT imaging of children. Whereas adults tend

to have elevated lymphocyte count at the beginning of the disease, in children the

lymphocytes were usually within the normal range. As the characteristics of COVID-19

differ between adults and children in multiple ways, specific criteria for the diagnosis and

treatment of COVID-19 in children are urgently needed.

Author contributions

(I) Conception and design: E Liu, Y Chen; (II) Administrative support: E Liu, Y Chen;

(III) Provision of study materials or patients: E Liu; (IV) Collection and assembly of

data: Z Wang, Q Zhou, C Wang, Q Shi, S Lu, Y Xun; (V) Data analysis and

interpretation: Z Wang, Q Zhou, C Wang, Y Ma, X Luo; (VI) Manuscript writing: All

authors; (VII) Final approval of manuscript: All authors.

Acknowledgments

We thank Janne Estill, Institute of Global Health of University of Geneva for providing

guidance and comments for our review. We thank all the authors for their wonderful

collaboration.

Funding

This work was supported by grants from National Clinical Research Center for Child

Health and Disorders (Children's Hospital of Chongqing Medical University, Chongqing,

China) (grant number NCRCCHD-2020-EP-01) to [Enmei Liu]; Special Fund for Key

Research and Development Projects in Gansu Province in 2020, to [Yaolong Chen]; The

fourth batch of "Special Project of Science and Technology for Emergency Response to

COVID-19" of Chongqing Science and Technology Bureau, to [Enmei Liu]; Special

funding for prevention and control of emergency of COVID-19 from Key Laboratory of

Evidence Based Medicine and Knowledge Translation of Gansu Province (grant number

No. GSEBMKT-2020YJ01), to [Yaolong Chen].

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

References

- 1. WHO Director-General's remarks at the media briefing on 2019-nCoV on 11 February 2020[Internet]. World Health Organization; c2020 [cited 2020 Apr 13]Available online: https://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020
- 2. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med 2020;382:727-33.
- 3. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020;395:565-74
- 4. Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med 2020;382(13):1199-207.
- 5. Yu P, Zhu J, Zhang Z, Han Y, Huang L. A familial cluster of infection associated with the 2019 novel coronavirus indicating potential person-to-person transmission during the incubation period. J Infect Dis 2020.
- 6. Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. J Med Virol 2020;92:401-2.
- 7. Bogoch II, Watts A, Thomas-Bachli A, Huber C, Kraemer MUG, Khan K. Potential for global spread of a novel coronavirus from China. J Travel Med 2020;27.
- 8. Wu J, Wu X, Zeng W, et al. Chest CT Findings in Patients with Corona Virus Disease 2019 and its Relationship with Clinical Features. Invest Radiol 2020;55:257-61.
- 9. Shen K, Yang Y, Wang T, et al. Diagnosis, treatment, and prevention of 2019 novel coronavirus infection in children: experts' consensus statement. World J Pediatr 2020.
- 10. Shen KL, Yang YH. Diagnosis and treatment of 2019 novel coronavirus infection in children: a pressing issue. World J Pediatr 2020.
- 11. Chen ZM, Fu JF, Shu Q. New coronavirus: new challenges for pediatricians. World J Pediatr 2020.
- 12. The novel coronavirus pneumonia diagnosis and treatment plan (trial version 7) [Internet]. National Health Commission of the People's Republic of China; c2020 [cited 2020 Apr 13]. Available online: http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.sht ml.
- 13. Global surveillance for COVID-19 disease caused by human infection with the 2019 novel coronavirus[Internet]. World Health Organization; c2020 [cited 2020 Apr 13]. Available online: https://www.who.int/publications-detail/global-surveillance-for-human-infection-with-novel-coronavirus-(2019-ncov).
- 14. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009;6:e1000100.
- 15. Tian J, Zhang J, Ge L, Yang K, Song F. The methodological and reporting quality of systematic reviews from China and the USA are similar. J Clin Epidemiol 2017;85:50-8.

- 16. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 2014;14:135.
- 17. Higgins, J. P. T, Altman, D. G, Gotzsche, P. C, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
- 18. Sterne J A C, Hernán M A, Reeves B C, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016,355: i4919.
- 19. Wells G,Shea B,O'Connell D,et al. NewCastle-Ottawa Quality Assessment Scale -- Cohort Studies. [cited 2020 Apr 13] Available online: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
- 20. Wells G,Shea B,O'Connell D,et al. NewCastle–Ottawa Quality Assessment Scale--Case Control Studies. [cited 2020 Apr 13] Available online: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
- 21. Rostom A, Dubé C, Cranney A, et al. Celiac Disease. Rockville (MD): Agency for Healthcare Research and Quality (US); 2004 Sep. (Evidence Reports/Technology Assessments, No. 104.) Appendix D. Quality Assessment Forms. [cited 2020 Apr 13] Available online: https://www.ncbi.nlm.nih.gov/books/NBK35156/
- 22. National Institute for Health and Care Excellence 2003 [cited 2020 Apr 13] Available online: https://www.nice.org.uk/guidance/cg3/documents/appendix-4-quality-of-case-series-form2.
- 23. DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials 2007;28:105-14.
- 24. Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011;64:383-94.
- 25. GRADEpro G D T. GRADEpro Guideline Development Tool [Software]. McMaster University, 2015 (developed by Evidence Prime, Inc.). [cited 2020 Apr 13] Available online: www. gradepro.org.
- 26. Guyatt GH, Oxman AD, Vist G, et al. GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias). J Clin Epidemiol 2011;64:407-15.
- 27. Guyatt GH, Oxman AD, Montori V, et al. GRADE guidelines: 5. Rating the quality of evidence--publication bias. J Clin Epidemiol 2011;64:1277-82.
- 28. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines 6. Rating the quality of evidence--imprecision. J Clin Epidemiol 2011;64:1283-93.
- 29. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 7. Rating the quality of evidence--inconsistency. J Clin Epidemiol 2011;64:1294-302.
- 30. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 8. Rating the quality of evidence--indirectness. J Clin Epidemiol 2011;64:1303-10.
- 31. Guyatt GH, Oxman AD, Sultan S, et al. GRADE guidelines: 9. Rating up the quality of evidence. J Clin Epidemiol 2011;64:1311-6.
- 32. Ge L, Tian JH, Li YN, et al. Association between prospective registration and overall reporting and methodological quality of systematic reviews: a meta-epidemiological study. J Clin Epidemiol 2018;93:45-55.
- 33. Deng H, Zhang Y, Wang Y, et al. Two cases of novel coronavirus infection in children. Pediatr Emerg Med 2020;27:81-3.
- 34. Cai J, Wang X, Ge Y, et al. First case of 2019 novel coronavirus infection in children in Shanghai. Chin J Pediatr 2020;58:86-7.
- 35. Zhang Y, Lin D, Xiao M, et al. 2019-novel coronavirus infection in a three-month-old baby. Chin J Pediatr 2020;58:182-4.
- 36. Wei M, Yuan J, Liu Y, et al. Novel Coronavirus Infection in Hospitalized Infants Under 1 Year of Age in China. JAMA 2020;323:1313-4.
- 37. Chen F, Liu Z, Zhang F, et al. First case of severe childhood novel coronavirus pneumonia in China. Chin J Pediatr 2020; 58: 179-82.

- 38. Zeng L, Tao X, Yuan W, et al. First case of neonate infected with novel coronavirus pneumonia in China. Chin J Pediatr 2020;58:E009.
- 39. Feng K, Yun Y, Wang X, et al. Analysis of CT features of 15 Children with 2019 novel coronavirus infection. Chin J Pediatr 2020;58:275-8.
- 40. Wang H, Duan X, Yan X, et al. A case of novel coronavirus pneumonia complicated with acute appendicitis in children. Chin J Pediatr Surg 2020;41.
- 41. Quan S, Li X, Ding D, et al. A case of novel coronavirus infection in children in Liaoning. Pediatr Emerg Med 2020.
- 42. Xiong D, Jiang J, Feng Y, et al. Novel coronavirus pneumonia in children: a report of two cases. Pediatr Emerg Med 2020.
- 43. Cai J, Xu J, Lin D, et al. A Case Series of children with 2019 novel coronavirus infection: clinical and epidemiological features. Clin Infect Dis 2020.
- 44. Wang D, Ju X, Xie F, et al. Clinical Analysis of 31 Cases of 2019 Novel Coronavirus Infection in Children From Six Provinces (Autonomous Region) of Northern China. Chin J Pediatr 2020;58:E011.
- 45. Tang A, Xu W, Shen M, et al. A retrospective study of the clinical characteristics of COVID-19 infection in 26 children. medRxiv 2020 [cited 2020 Apr 13]. Available online: https://doi.org/10.1101/2020.03.08.20029710.
- 46. Liu W, Zhang Q, Chen J, et al. Detection of Covid-19 in Children in Early January 2020 in Wuhan, China. N Engl J Med 2020;382:1370-1.
- 47. Lu X, Zhang L, Du H, et al. SARS-CoV-2 Infection in Children. N Engl J Med 2020.
- 48. Ma H, Hu J, Tian J, et al. Visualizing the novel coronavirus (COVID-19) in children: What we learn from patients at Wuhan Children's Hospital. SSRN 2020. [cited 2020 Apr 13]. Available online: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3550012
- 49. Zhao R, Shen X, Xu K, et al. A case of 2019 novel coronavirus infection in children. Zhejiang Medical Journal 2020.
- 50. Li Q, Peng X, Sun Z, et al. Clinical and imaging characteristics of children with corona virus disease 2019 (COVID-19). Radiol Practice 2020;35:277-80.
- 51. Zhang X, Ma Y, Xiao J, et al. Clinical characteristics of novel coronavirus pneumonia in children in Jinan. Journal of Shandong University 2020.
- 52. Zhang G, Zhang A, Hunag L, et al. Twin girls infected with SARS-CoV-2. Chin J Contemp Pediatr 2020;22:221-5.
- 53. Liu M, Wan X, Tu X, et al. Family cluster of child SARS-CoV-2 infections: a case report. Medical Journal of Wuhan University 2020. Chinese.
- 54. Xiao K, Shui L, Pang X, et al. The clinical features of the 143 patients with COVID-19 in North-East of Chongging. Journal of Third Military Medical University 2020.
- 55. Xu H, Liu E, Xie J, et al. A follow-up study of children infected with SARS-CoV-2 from Western China. Clinical Infectious Diseases. Forthcoming 2020.
- 56. Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 2020; 395:514-23.
- 57. Kam KQ, Yung CF, Cui L, et al. A Well Infant with Coronavirus Disease 2019 (COVID-19) with High Viral Load. Clin Infect Dis 2020.
- 58. Park JY, Han MS, Park KU, et al. First Pediatric Case of Coronavirus Disease 2019 in Korea. J Korean Med Sci 2020;35:e124.
- 59. Du W, Yu J, Wang H, et al. Clinical characteristics of COVID-19 in children compared with adults outside of Hubei Province in China. SSRN 2020 [cited 2020 Apr 13]. Available online: http://dx.doi.org/10.2139/ssrn.3546097
- 60. Liu H, Liu F, Li J, et al. Clinical and CT imaging features of the COVID-19 pneumonia: Focus on pregnant women and children. J Infect 2020;S0163-4453(20)30118-3.

- 61. Wang S, Guo L, Chen L, et al. A case report of neonatal COVID-19 infection in China. Clin Infect Dis 2020.
- 62. Rahimzadeh G, Ekrami N.M, Kadkhodaei E.F, et al. COVID-19 Infection in Iranian Children: A Case Series of 9 Patients. Journal of Pediatrics Review 2020;8(2):139-44.
- 63. Ji L, Chao S, Wang Y, et al. Clinical features of pediatric patients with COVID-19: a report of two family cluster cases. World J Pediatr 2020.
- 64. Xu Y, Li X, Zhu B, et al. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. Nature Medicine 2020.
- 65. Xia W, Shao J, Guo Y, et al. Clinical and CT features in pediatric patients with COVID-19 infection: Different points from adults. Pediatr Pulmonol 2020.
- 66. Dong Y, Mo X, Hu Y, et al. Epidemiological Characteristics of 2143 Pediatric Patients With 2019 Coronavirus Disease in China. Pediatrics 2020.
- 67. Xing Y, Ni W, Wu Q, et al. Prolonged presence of SARS-CoV-2 in feces of pediatric patients during the convalescent phase. medRxiv 2020 [cited 2020 Apr 13]. Available online: https://doi.org/10.1101/2020.03.11.20033159.
- 68. Yu H, Cai Q, Dai X, et al. The clinical and epidemiological features and hints of 82 confirmed COVID-19 pediatric cases aged 0-16 in Wuhan, China. medRxiv 2020 [cited 2020 Apr 13]. Available online: https://doi.org/10.1101/2020.03.15.20036319
- 69. Liu J, Luo W, Deng Zh, et al. Clinical and epidemiological characteristics of 91 children conformed with COVID-19. Chin J Nosocomiol. 2020;30:1645-9. Chinese.
- 70. Ma Y, Xia Sh, Wang M, et al. Clinical features of children with SARS-CoV-2 infection: an analysis of 115 cases. Chin J Contemp Pediatr 2020;22:1-4.
- 71. Qian G, Yang N, Ma AHY, et al. A COVID-19 Transmission within a family cluster by presymptomatic infectors in China. Clin Infect Dis 2020.
- 72. Qiu H, Wu J, Hong L, et al. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. Lancet Infect Dis 2020.
- 73. Zheng F, Liao C, Fan Q, et al. Clinical Characteristics of Children with Coronavirus Disease 2019 in Hubei, China. Curr Med Sci 2020.
- 74. Sun D, Li H, Lu X, et al. Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center's observational study. World J Pediatr 2020.
- 75. Dong X, Cao Y, Lu X, et al. Eleven Faces of Coronavirus Disease 2019. Allergy 2020.
- 76. Wu Q, Xing Y, Shi L, et al. Epidemiological and Clinical Characteristics of Children with Coronavirus Disease 2019. medRxiv 2020 [cited 2020 Apr 13]. Available online: https://doi.org/10.1101/2020.03.19.20027078.
- 77. Su L, Ma X, Yu H, et al. The different clinical characteristics of corona virus disease cases between children and their families in China the character of children with COVID-19. Emerg Microbes Infect 2020;9:707-13.
- 78. Le H.T, Nguyen L.V, Tran D.M, et al. The first infant case of COVID-19 acquired from a secondary transmission in Vietnam. Lancet Child Adolesc Health 2020.
- 79. Zhong Zh, Xie X, Huang W, et al. Chest CT findings and clinical features of coronavirus disease 2019 in children. J Cent South Univ (Med Sci) 2020;45:236-42.
- 80. Yang L, Li Zh, Xu H, et al. Epidemiological and clinical characteristics of 10 children with coronavirus disease (COVID-19) in Jinan. Journal of Shandong University(Health Sciences) 2020;58:1-4.
- 81. Tang A, Tong ZD, Wang HL, et al. Detection of Novel Coronavirus by RT-PCR in Stool Specimen from Asymptomatic Child, China. Emerg Infect Dis. 2020;26.
- 82. Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) in China. Chin J Epidemiol 2020;41:145-51.
- 83. Zhang J, Dong X, Cao Y, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020.

- 84. Li Y, Wang W, Lei Y, et al. Comparison of the Clinical Characteristics Between RNA Positive and Negative Patients Clinically Diagnosed With 2019 Novel Coronavirus Pneumonia. Chin J Tuberc Respir Dis 2020;43:E023.
- 85. Chen L, Liu H, Liu W, et al. Analysis of Clinical Features of 29 Patients With 2019 Novel Coronavirus Pneumonia. Chin J Tuberc Respir Dis 2020;43, 203-8.
- 86. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395: 497-506.
- 87. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395:507-13.
- 88. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020.
- 89. Hu Z, Song C, Xu C, et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. Sci China Life Sci 2020.
- 90. Zhao D, Jin R, Liu Z, Yin W. Recommendation for the diagnosis and treatment of novel coronavirus infection in children in Hubei (Trial version 1). Chin J Contemp Pediatr 2020,22:96-9.
- 91. Chen Zh, Fu J, Shu Q, et al. Diagnosis and treatment recommendation for pediatric coronavirus disease-19. Journal of Zhejiang University (Medical Sciences) 2020;49:1-8.
- 92. Xu H, Luo Zh, Xu F. Diagnosis and treatment of the 2019 novel coronavirus infection in children. (Trial version 2 of Children's Hospital of Chongqing Medical University) [Internet]. Journal of Pediatric Pharmacy; 2020 [cited 2020 Apr 13]. Available online: http://kns.cnki.net/kcms/detail/50.1156.R.20200226.1309.002.html.
- 93. Wang M, Yue S. The programme for prevention and control of SARS-CoV-2 infection in neonates in Hunan Provence. China J Mod Med 2020:65-71
- 94. Li Z, Shen K, Wei X, et al. Clinical analysis of pediatric SARS cases in Beijing. Chin J Pediatr 2003;41:574-7.
- 95. Memish ZA, Al-Tawfiq JA, Assiri A, et al. Middle East respiratory syndrome coronavirus disease in children. Pediatr Infect Dis J 2014;33:904-6.
- 96. Young BE, Ong SWX, Kalimuddin S, et al. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. JAMA 2020;e203204.
- 97. Ong SWX, Tan YK, Chia PY, et al. Air, Surface Environmental, and Personal Protective Equipment Contamination by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) From a Symptomatic Patient. JAMA 2020;e203227.
- 98. Xu Y, Li X, Zhu B, et al. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. Nature Medicine 2020; 1-4.
- 99. Memish Z A , Al-Tawfiq J A , Assiri A , et al. Middle East Respiratory Syndrome Coronavirus Disease in Children. Pediatr Infect Dis J 2014;33:904-6.
- 100. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis 2020.
- 101. Pei Y, Liu W, Ismail B.M, et al. COVID-19: Children Comparison with Adults Based on the Latest Data. SSRN 2020 [cited 2020 Apr 13]. Available online: http://dx.doi.org/10.2139/ssrn.3550063
- 102. Li L, Huang T, Wang Y, et al. COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol 2020.
- 103. Qian K, Deng Y, Tai Y, et al. Clinical Characteristics of 2019 Novel Infected Coronavirus Pneumonia: A Systemic Review and Meta-analysis. medrxiv 2020 [cited 2020 Apr 13]. Available online: https://doi.org/10.1101/2020.02.14.20021535
- 104. Sun P, Qie S, Liu Z, et al. Clinical characteristics of hospitalized patients with SARS-CoV-2 infection: A single arm meta-analysis. J Med Virol 2020.

- 106. Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr 2020.
- 107. WHO Handbook for Guideline Development (2nd edition)[Internet]. World Health Organization; c2020 [cited 2020 Apr 13]. Available online: https://apps.who.int/medicinedocs/en/m/abstract/Js22083en/.

Supplementary Material

Contents

Supplementary Material 1-Search strategy

PubMed

- #1 "Epidemiological Studies"[Title/Abstract]
- #2 "Epidemiologic* Study"[Title/Abstract]
- #3 "Epidemiological characteristics"[Title/Abstract]
- #4 "Clinical features"[Title/Abstract]
- #5 "Clinical characteristics"[Title/Abstract]
- #6 "Clinical Presentation"[Title/Abstract]
- #7 #1-#6/ OR
- #8 "COVID-19"[Supplementary Concept]
- #9 "Severe Acute Respiratory Syndrome Coronavirus 2"[Supplementary Concept]
- #10 "COVID-19"[Title/Abstract]
- #11 "SARS-COV-2"[Title/Abstract]
- #12 "Novel coronavirus" [Title/Abstract]
- #13 "2019-novel coronavirus" [Title/Abstract]
- #14 "coronavirus disease-19" [Title/Abstract]
- #15 "coronavirus disease 2019" [Title/Abstract]
- #16 "COVID19" [Title/Abstract]
- #17 "Novel CoV" [Title/Abstract]
- #18 "2019-nCoV" [Title/Abstract]
- #19 "2019-CoV" [Title/Abstract]
- #20 "Wuhan-Cov" [Title/Abstract]
- #21 "Wuhan Coronavirus" [Title/Abstract]
- #22 "Wuhan seafood market pneumonia virus" [Title/Abstract]
- #23 #8-#22/ OR
- #24 #7 AND #23

EMBASE

- #1 'COVID-19':ab,ti
- #2 'SARS-COV-2':ab,ti
- #3 'novel coronavirus':ab,ti
- #4 '2019-novel coronavirus':ab,ti

- #5 'coronavirus disease-19':ab,ti
- #6 'coronavirus disease 2019':ab,ti
- #7 'COVID19':ab,ti
- #8 'novel cov':ab,ti
- #9 '2019-ncov':ab,ti
- #10 '2019-cov':ab,ti
- #11 'wuhan-cov':ab,ti
- #12 'wuhan coronavirus':ab,ti
- #13 'wuhan seafood market pneumonia virus':ab,ti
- #14 #1-13/OR
- #15 'epidemiological studies':ab,ti
- #16 'epidemiologic* study':ab,ti
- #17 'epidemiological characteristics':ab,ti
- #18 'clinical feature'/exp
- #19 'clinical features':ab,ti
- #20 'clinical characteristics':ab,ti
- #21 'clinical presentation':ab,ti
- #22 #15-21/OR
- #23 #14 AND #22
- #24 #23 AND [medline]/lim
- #25 #23 NOT #24

Web of Science

- #1 TOPIC: "Epidemiological Studies"
- #2 TOPIC: "Epidemiologic* Study"
- #3 TOPIC: "Epidemiological characteristics"
- #4 TOPIC: "Clinical features"
- #5 TOPIC: "Clinical characteristics"
- #6 TOPIC: "Clinical Presentation"
- #7 #1-6/OR
- #8 TOPIC: "COVID-19"
- #9 TOPIC: "SARS-COV-2"
- #10 TOPIC: "Novel coronavirus"
- #11 TOPIC: "2019-novel coronavirus"
- #12 TOPIC: "coronavirus disease-19"
- #13 TOPIC: "coronavirus disease 2019"
- #14 TOPIC: "COVID19"
- #15 TOPIC: "Novel CoV"
- #16 TOPIC: "2019-nCoV"
- #17 TOPIC: "2019-CoV"
- #18 TOPIC: "Wuhan-Cov"
- #19 TOPIC: "Wuhan Coronavirus"
- #20 TOPIC: "Wuhan seafood market pneumonia virus"
- #21 #8-20/ OR
- #22 #7 AND #21

Cochrane

- #1 "COVID-19":ti,ab,kw
- #2 "SARS-COV-2":ti.ab.kw
- #3 "Novel coronavirus":ti,ab,kw
- #4 "2019-novel coronavirus" :ti,ab,kw
- #5 "Novel CoV" :ti,ab,kw
- #6 "2019-nCoV" :ti,ab,kw

- #7 "coronavirus disease-19" :ti,ab,kw
- #8 "coronavirus disease 2019" :ti,ab,kw
- #9 "COVID19" :ti,ab,kw
- #10 "Wuhan-Cov" :ti,ab,kw
- #11 "Wuhan Coronavirus" :ti,ab,kw
- #12 "Wuhan seafood market pneumonia virus" :ti,ab,kw
- #13 #1-12/OR
- #14 "Epidemiological Studies":ti,ab,kw
- #15 "Epidemiologic* Study":ti,ab,kw
- #16 "Epidemiological characteristics":ti,ab,kw
- #17 "Clinical features":ti,ab,kw
- #18 "Clinical characteristics":ti,ab,kw
- #19 "Clinical Presentation":ti,ab,kw
- #20 #14-19/ OR
- #21 #13 AND #20

CBM

- #1 "新型冠状病毒"[常用字段:智能]
- #2 "COVID-19"[常用字段:智能]
- #3 "COVID 19"[常用字段:智能]
- #4 "2019-nCoV"[常用字段:智能]
- #5 "2019-CoV"[常用字段:智能]
- #6 "SARS-CoV-2"[常用字段:智能]
- #7 "武汉冠状病毒"[常用字段:智能]
- #8 #1-7/OR
- #9 "流行病学"[中文标题:智能]
- #10 "临床表现"[中文标题:智能]
- #11 "临床特征"[中文标题:智能]
- #12 "临床特点"[中文标题:智能]
- #13 #9-12/ OR
- #14 #8 AND #13

WanFang

- #1 "新型冠状病毒"[主题]
- #2 "COVID-19"[主题]
- #3 "COVID 19"[主题]
- #4 "2019-nCoV"[主题]
- #5 "2019-CoV"[主题]
- #6 "SARS-CoV-2"[主题]
- #7 "武汉冠状病毒"[主题]
- #8 #1-#7/ OR
- #9 "流行病学"[题名]
- #10 "临床特点"[题名]
- #11 "临床特征"[题名]
- #12 "临床表现"[题名]
- #13 #9-12/ OR
- #14 #8 AND #13

CNKI

#1 "新型冠状病毒"[主题]

- #3 "COVID 19"[主题]
- #4 "2019-nCoV"[主题]
- #5 "2019-CoV"[主题]
- #6 "SARS-CoV-2"[主题]
- #7 "武汉冠状病毒"[主题]
- #8 #1-7/ OR
- #9 "流行病学"[篇名]
- #10 "临床特点"[篇名]
- #11 "临床特征"[篇名]
- #12 "临床表现"[篇名]
- #13 #9-12 OR
- #14 #8 AND #13

Supplementary Material 2-Risk of bias

Table A. National Institute for Health and Care Excellence

Deng 2020 (33) no yes yes no yes no yes no 4 Cai 2020 (34) no yes yes no yes no yes no yes no 4 Zhang 2020 (35) no yes yes yes no no yes no 4 Wei 2020 (36) yes yes yes yes no no yes no 5 Chen 2020 (37) no yes yes yes no yes yes no yes no yes yes no yes	Author	1. Case series collected in more than one centre, i.e. multi-centre study	2. Is the hypothesis/aim/obj ective of the study clearly described?	3. Are the inclusion and exclusion criteria (case definition) clearly reported?	4. Is there a clear definition of the outcomes reported?	5. Were data collected prospectively?	6. Is there an explicit statement that patients were recruited consecutively?	7. Are the main findings of the study clearly described?	8. Are outcomes stratified? (e.g., by disease stage, abnormal test results, patient characteristics)	Total Score
Zhang 2020 (35) no yes yes yes yes no yes no yes Wei 2020 (36) yes yes yes yes no no yes no 5 Chen 2020 (37) no yes yes yes no yes no 5 Zeng 2020 (38) no yes yes yes no yes no yes no 5 Feng 2020 (39) no yes yes yes no no yes no yes yes pes no yes yes pes no no yes no 4 yes no 4 yes no 4 yes no 4 4 Xiong 2020 (41) no yes yes no yes no <t< td=""><td>Deng 2020 (33)</td><td>no</td><td>yes</td><td>yes</td><td>no</td><td>yes</td><td>no</td><td>yes</td><td>no</td><td>4</td></t<>	Deng 2020 (33)	no	yes	yes	no	yes	no	yes	no	4
Wei 2020 (36) yes yes yes yes yes yes no no yes no 5 Chen 2020 (37) no yes yes yes no yes no 5 Zeng 2020 (38) no yes yes yes no no yes no 5 Feng 2020 (39) no yes yes no no yes yes 5 Wang 2020 (40) no yes yes no yes no yes no yes no 4 Quan 2020 (41) no yes yes no yes no yes no yes no yes no 4 Cai 2020 (43) yes yes yes yes no yes no yes no yes no yes no 5 Wang 2020 (44) yes yes yes yes yes no	Cai 2020 (34)	no	yes	yes	no	yes	no	yes	no	4
Chen 2020 (37) no yes yes yes yes no yes no 5 Zeng 2020 (38) no yes yes yes no yes no 5 Feng 2020 (39) no yes yes no no yes yes 5 Wang 2020 (40) no yes yes no yes no yes no 4 Quan 2020 (41) no yes yes no yes no yes no 4 Xiong 2020 (42) no yes yes no yes no yes no 4 Cai 2020 (43) yes yes yes no no yes no yes no yes no yes no 5 Wang 2020 (44) yes yes yes yes no no yes no yes no yes no yes no y	Zhang 2020 (35)	no	yes	yes	no	yes	no	yes	no	4
Zeng 2020 (38) no yes yes yes yes no yes yes pes pes <t< td=""><td>Wei 2020 (36)</td><td>yes</td><td>yes</td><td>yes</td><td>yes</td><td>no</td><td>no</td><td>yes</td><td>no</td><td>5</td></t<>	Wei 2020 (36)	yes	yes	yes	yes	no	no	yes	no	5
Feng 2020 (39) no yes yes yes no no yes yes pes yes pes pes pes pes pes pes pes pes no 4 Quan 2020 (41) no yes yes no yes no yes no yes no 4 Xiong 2020 (42) no yes yes no yes no yes no yes no 4 Cai 2020 (43) yes yes yes no yes no yes no yes no 5 Wang 2020 (44) yes yes yes yes no no yes no 5 Tang 2020 (45) no yes yes yes no no yes yes <td>Chen 2020 (37)</td> <td>no</td> <td>yes</td> <td>yes</td> <td>yes</td> <td>yes</td> <td>no</td> <td>yes</td> <td>no</td> <td>5</td>	Chen 2020 (37)	no	yes	yes	yes	yes	no	yes	no	5
Wang 2020 (40) no yes yes no yes no yes no 4 Quan 2020 (41) no yes yes no yes no yes no 4 Xiong 2020 (42) no yes yes no yes no yes no yes no 4 Cai 2020 (43) yes yes yes no no yes no yes no 5 Wang 2020 (44) yes yes yes yes no no yes no 5 Tang 2020 (45) no yes yes yes no no yes no 4 Liu 2020 (46) yes yes yes no no yes ye	Zeng 2020 (38)	no	yes	yes	yes	yes	no	yes	no	5
Quan 2020 (41) no yes yes no yes no yes Xiong 2020 (42) no yes yes no yes no 4 Cai 2020 (43) yes yes yes no yes no yes no 5 Wang 2020 (44) yes yes yes yes no no yes no 5 Tang 2020 (45) no yes yes yes no no yes no 4 Liu 2020 (46) yes yes yes yes no no yes yes 9 Lu 2020 (47) no yes yes no no no yes yes yes 5 Ma 2020 (48) no yes no no no no yes no <td< td=""><td>Feng 2020 (39)</td><td>no</td><td>yes</td><td>yes</td><td>yes</td><td>no</td><td>no</td><td>yes</td><td>yes</td><td>5</td></td<>	Feng 2020 (39)	no	yes	yes	yes	no	no	yes	yes	5
Xiong 2020 (42) no yes yes no yes no yes no 4 Cai 2020 (43) yes yes yes no yes no yes no 5 Wang 2020 (44) yes yes yes yes no no yes no 5 Tang 2020 (45) no yes yes yes no no yes no 4 Liu 2020 (46) yes yes yes yes no no yes yes yes yes 6 Lu 2020 (47) no yes yes no no no yes yes yes 5 Ma 2020 (48) no yes no no no no yes no yes no 5 Zhao 2020 (49)	Wang 2020 (40)	no	yes	yes	no	yes	no	yes	no	4
Cai 2020 (43) yes yes yes no yes no yes no 5 Wang 2020 (44) yes yes yes no no no yes no 5 Tang 2020 (45) no yes yes no no no yes no 4 Liu 2020 (46) yes yes yes no no yes yes 6 Lu 2020 (47) no yes yes no no yes yes yes yes 5 Ma 2020 (48) no yes no no no no yes yes 3 Zhao 2020 (49) no yes yes no no no yes yes no 1 Li 2020 (50) yes yes yes yes no no yes no 5 Zhang 2020 (51) no yes yes yes no	Quan 2020 (41)	no	yes	yes	no	yes	no	yes	no	4
Wang 2020 (44) yes yes yes yes no no yes no 5 Tang 2020 (45) no yes yes yes no no yes no 4 Liu 2020 (46) yes yes yes no no yes yes yes 6 Lu 2020 (47) no yes yes no no yes yes yes yes 5 Ma 2020 (48) no yes no no no no yes yes yes 3 Zhao 2020 (49) no yes yes no no no yes yes yes yes no 5 Li 2020 (50) yes yes yes no no no yes no 5 Zhang 2020 (51) no yes no no no no yes yes yes 3 Zhang 2020 (52) <	Xiong 2020 (42)	no	yes	yes	no	yes	no	yes	no	4
Tang 2020 (45) no yes yes no no yes no 4 Liu 2020 (46) yes yes yes no no yes yes 6 Lu 2020 (47) no yes yes no yes no yes yes yes 5 Ma 2020 (48) no yes no no no no yes yes yes yes yes yes 4 Li 2020 (49) no yes yes yes no no yes yes no yes no 5 Li 2020 (50) yes yes yes yes no no yes no 5 Zhang 2020 (51) no yes yes yes no no yes yes no 4 Zhang 2020 (52) no yes no no no yes yes 3	Cai 2020 (43)	yes	yes	yes	no	yes	no	yes	no	5
Liu 2020 (46) yes yes yes yes yes no no yes yes yes no yes yes no yes yes 5 Lu 2020 (47) no yes yes no no yes yes no yes yes 5 Ma 2020 (48) no yes no no no no yes yes yes 3 Zhao 2020 (49) no yes no yes no no yes yes yes 4 Li 2020 (50) yes yes yes yes yes no no no yes no 5 Zhang 2020 (51) no yes no no no yes yes no no no yes no 4 Zhang 2020 (52) no yes no no no yes yes yes no no no yes yes no yes yes yes no no no yes yes yes yes yes no no no yes yes yes yes yes yes yes no no no yes yes yes yes yes yes yes no no yes yes yes yes yes yes yes no no no yes	Wang 2020 (44)	yes	yes	yes	yes	no	no	yes	no	5
Lu 2020 (47) no yes yes no yes yes 5 Ma 2020 (48) no yes no no no no yes yes 3 Zhao 2020 (49) no yes no no no yes yes yes yes no no yes no 5 Zhang 2020 (50) yes yes yes yes no no no yes no 4 Zhang 2020 (52) no yes no no no yes yes 3	Tang 2020 (45)	no	yes	yes	yes	no	no	yes	no	4
Ma 2020 (48) no yes no no no no yes yes 3 Zhao 2020 (49) no yes no no no yes yes 4 Li 2020 (50) yes yes yes no no yes no 5 Zhang 2020 (51) no yes yes yes no no yes no 4 Zhang 2020 (52) no yes no no no yes yes 3	Liu 2020 (46)	yes	yes	yes	yes	no	no	yes	yes	6
Zhao 2020 (49) no yes no yes yes yes 4 Li 2020 (50) yes yes yes no no no yes no 5 Zhang 2020 (51) no yes yes yes no no yes no 4 Zhang 2020 (52) no yes no no no no yes yes 3	Lu 2020 (47)	no	yes	yes	no	yes	no	yes	yes	5
Li 2020 (50) yes yes yes yes yes no no yes no 5 Zhang 2020 (51) no yes yes yes no no no yes no 4 Zhang 2020 (52) no yes no no no yes yes 3	Ma 2020 (48)	no	yes	no	no	no	no	yes	yes	3
Zhang 2020 (51) no yes yes yes no no yes no 4 Zhang 2020 (52) no yes no no no yes yes 3	Zhao 2020 (49)	no	yes	no	yes	no	no	yes	yes	4
Zhang 2020 (52) no yes no no no no yes yes 3	Li 2020 (50)	yes	yes	yes	yes	no	no	yes	no	5
	Zhang 2020 (51)	no	yes	yes	yes	no	no	yes	no	4
Liu 2020 (53) no yes no no no no yes yes 3	Zhang 2020 (52)	no	yes	no	no	no	no	yes	yes	3
	Liu 2020 (53)	no	yes	no	no	no	no	yes	yes	3

Xiao 2020 (54)	no	yes	yes	yes	no	no	yes	yes	5
Xu 2020 (55)	yes	yes	yes	yes	no	no	yes	yes	5
Chan 2020 (56)	no	yes	yes	yes	no	yes	yes	yes	6
Kam 2020 (57)	no	yes	no	yes	no	no	yes	yes	4
Park 2020 (58)	no	yes	no	no	no	no	yes	yes	3
Du 2020 (59)	yes	yes	yes	yes	no	yes	yes	yes	7
Liu 2020 (60)	yes	yes	no	yes	no	no	yes	yes	5
Wang 2020 (61)	no	yes	no	yes	no	no	yes	yes	4
Rahimzadeh 2020 (62)	yes	yes	no	no	no	no	yes	yes	4
Ji 2020 (63)	no	yes	no	yes	no	no	yes	yes	4
Xu 2020 (64)	no	yes	yes	no	no	no	yes	yes	4
Xia 2020 (65)	no	yes	yes	yes	no	no	yes	no	4
Dong 2020 (66)	yes	yes	yes	yes	no	no	yes	yes	6
Xing 2020 (67)	no	yes	yes	yes	no	no	yes	yes	5
Yu 2020 (68)	no	yes	yes	no	no	no	yes	yes	4
Liu 2020 (69)	no	yes	yes	yes	no	no	yes	yes	5
MA 2020 (70)	no	yes	yes	yes	no	no	yes	yes	5
Qian 2020 (71)	no	yes	no	no	no	no	yes	yes	3
Zhang 2020 (73)	yes	yes	yes	yes	no	no	yes	yes	6
Sun 2020 (74)	no	yes	yes	yes	no	no	yes	no	4
Dong 2020 (75)	yes	yes	no	yes	no	no	yes	yes	5
Wu 2020 (76)	yes	yes	yes	yes	no	no	yes	no	5
Su 2020 (77)	no	yes	yes	yes	no	no	yes	yes	5
Le 2020 (78)	no	yes	no	no	no	no	yes	yes	3
Zhong 2020 (79)	no	yes	yes	yes	no	no	yes	yes	5
Liu 2020 (80)	yes	yes	yes	yes	no	no	yes	yes	6
Tang 2020 (81)	no	yes	no	no	no	no	yes	yes	3

Table B. Newcastle-Ottawa Scale

		SE	LECTION		COMPARABILITY		OUTCOME	
Author	1) Representativeness of the Exposed Cohort	2) Selection of the Non- Exposed Cohort	3) Ascertainment of Exposure	4) Demonstration That Outcome of Interest Was Not Present at Start of Study	1) Comparability of Cohorts on the Basis of the Design or Analysis	1) Assessment of Outcome	2) Was Follow- Up Long Enough for Outcomes to Occur	3) Adequacy of Follow Up of Cohorts
Qiu 2020 (72)	*		*	*		*		

Supplementary Material 3-GRADE evidence profile

Symptoms and Imaging f	indings								
	Certainty assess	ment				№ of pa	atients	Effect Value	
№ of studies	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Total	Event	(95% CI)	Certainty
The overall symptoms									
No Symptom (17)	serious ¹	serious ²	not serious	not serious	none	1396	218	19% (14%, 23%)	⊕⊕○○ LOW
Mild symptom (19)	serious ¹	serious ²	not serious	not serious	none	1540	1396	94% (90%, 98%)	⊕⊕○○ LOW
Severe symptom (19)	serious ¹	not serious	not serious	not serious	none	1525	49	3% (2%, 4%)	⊕⊕⊕○ MODERATE
More than one sign or symptom (15)	serious ¹	serious ²	not serious	not serious	none	281	104	35% (21%, 48%)	⊕⊕○○ LOW
Specific symptoms									
Fever (23)	serious ¹	serious ²	not serious	not serious	none	890	418	48% (39%, 56%)	⊕⊕○○ LOW
Cough (21)	serious ¹	serious ²	not serious	not serious	none	766	352	39% (30%, 48%)	⊕⊕○○ LOW
Fever and Cough (7)	serious ¹	serious ²	not serious	not serious	none	203	76	30% (18%, 42%)	⊕⊕○○ LOW
Sputum production (4)	serious ¹	serious ²	not serious	serious ³	none	292	92	19% (0%, 44%)	⊕○○○ VERY LOW
Rhinorrhoea (9)	serious ¹	not serious	not serious	not serious	none	380	37	9% (6%, 12%)	⊕⊕⊕○ MODERATE
Shortness of breath / Dyspnoea (6)	serious ¹	serious ²	not serious	not serious	none	343	64	9% (0%, 19%)	⊕⊕○○ LOW
Myalgia or fatigue (10)	serious ¹	serious ²	not serious	not serious	none	524	49	8% (5%, 12%)	⊕⊕○○ LOW
Diarrhoea (10)	serious ¹	not serious	not serious	not serious	none	528	42	7% (5%, 9%)	⊕⊕⊕○ MODERATE
Nausea or vomiting (8)	serious ¹	not serious	not serious	not serious	none	430	27	6% (4%, 9%)	⊕⊕⊕○ MODERATE
Nasal obstruction (6)	serious ¹	not serious	not serious	not serious	none	262	19	6% (3%, 9%)	⊕⊕⊕○ MODERATE
Sore throat (10)	serious ¹	not serious	not serious	not serious	none	244	20	6% (2%, 10%)	⊕⊕⊕○ MODERATE

Headache (7)	serious ¹	not serious	not serious	not serious	none	289	14	4% (1%, 6%)	⊕⊕⊕○ MODERATE
Imaging findings									
Abnormal (18)	serious1	serious ²	not serious	not serious	none	674	447	66% (55%, 77%)	⊕⊕○○ LOW
Unilateral pneumonia (10)	serious ¹	serious ²	not serious	not serious	none	347	111	31% (20%, 43%)	⊕⊕○○ LOW
Bilateral pneumonia (13)	serious ¹	serious ²	not serious	not serious	none	597	146	28% (20%, 36%)	⊕⊕○○ LOW
Ground-glass opacity (14)	serious ¹	serious ²	not serious	not serious	none	727	246	35% (26%, 44%)	⊕⊕○○ LOW

Laboratory results								
№ of studies	Certainty assess	sment				№ of patients	Effect Value	Certainty
	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Total	- (95% CI)	
Blood routine values								
Leucocytes (\times 10 9 /L) (12)	serious1	not serious	not serious	not serious	none	465	6.25 (5.97, 6.54)	⊕⊕⊕○ MODERAT
Lymphocytes (× 10 ⁹ /L) (9)	serious ¹	serious ²	not serious	not serious	none	356	2.84 (2.55, 3.13)	⊕⊕○○ LOW
Neutrophils (× 10 ⁹ /L) (5)	$serious^1$	serious ²	not serious	not serious	none	236	2.70 (2.10, 3.31)	⊕⊕○○ LOW
Platelets (× 10°/L) (7)	serious ¹	serious ²	not serious	not serious	none	133	264.65 (254.17, 275.12)	⊕⊕○○ LOW
Haemoglobin (g/L) (8)	serious ¹	serious ²	not serious	not serious	none	304	127.21 (123.38, 131.04)	⊕⊕○○ LOW
Blood biochemistry								
Albumin (g/L) (2)	serious ¹	not serious	not serious	not serious	none	41	45.30 (45.13, 45.47)	⊕⊕⊕○ MODERAT
Alanine aminotransferase (U/L) (8)	serious ¹	serious ²	not serious	serious ³	none	306	20.46 (14.51, 26.41)	⊕○○○ VERY LOW
Aspartate aminotransferase (U/L) (7)	serious ¹	serious ²	not serious	not serious	none	281	32.04 (30.25, 33.83)	⊕⊕○○ LOW
Total bilirubin (μmol/L) (2)	serious ¹	serious ²	not serious	serious ³	none	41	8.14 (1.45, 14.82)	⊕○○○ VERY LOV
Blood urea nitrogen (mmol/L) (5)	serious ¹	not serious	not serious	not serious	none	240	3.81 (3.43, 4.18)	⊕⊕⊕○ MODERAT

Creatinine (µmol/L) (5)	serious ¹	serious ²	not serious	serious ³	none	240	41.60 (32.98, 50.22)	⊕○○○ VERY LOW
Creatine kinase (U/L) (3)	serious ¹	serious ²	not serious	not serious	none	59	104.37 (95.66, 113.08)	⊕⊕○○ LOW
Lactate dehydrogenase (U/L) (7)	serious ¹	serious ²	not serious	serious ³	none	334	264.43 (241.85, 287.02)	⊕○○○ VERY LOW
Myoglobin (ug/L) (2)	serious ¹	not serious	not serious	not serious	none	23	15.33 (11.18, 19.48)	⊕⊕⊕○ MODERATE
Procalcitonin (g/L) (7)	serious ¹	not serious	not serious	not serious	none	398	0.06 (0.00, 0.16)	⊕⊕⊕○ MODERATE
CRP (mg/L) (8)	serious ¹	serious ²	not serious	not serious	none	348	5.05 (1.86, 8.24)	⊕⊕○○ LOW
Coagulation function								
Activated partial thromboplastin time (s) (2)	serious ¹	serious ²	not serious	serious ³	none	38	37.59 (28.69, 46.48)	⊕○○○ VERY LOW
Prothrombin time (s) (4)	serious ¹	serious ²	not serious	not serious	none	223	12.25 (11.30, 13.20)	⊕⊕○○ LOW
D-dimer (mg/L) (8)	serious ¹	not serious	not serious	not serious	none	261	0.33 (0.17, 0.49)	⊕⊕⊕○ MODERATE

Explanations

- downgrade one level: The risk of bias is high due to the limitations of study design.
 downgrade one level: Heterogeneity of data synthesis results, I²> 50%.
 downgrade one level: Sample size is less than optimal information sample (OIS).
 upgrade two levels: Large magnitude of effect, RR>5.
 Outcome (number of studies)

Supplementary Material 4-Case report summary

Table A. Symptom

Study ID	Number	Mild symptom	Severe symptom	Fever	Cough	Fever and Cough	Sputum production	Myalgia or fatigue	Sore throat	Shortness of breath / Dyspnoea	Diarrhoea
Deng 2020 (33)	2	2/2	0/2	1/2	0/2	0/2	0/2	0/2	1/2	0/2	0/2
Cai 2020 (34)	1	1/1	0/1	1/1	1/1	1/1	0/1	0/1	0/1	0/1	0/1
Zhang 2020 (35)	1	1/1	0/1	1/1	0/1	0/1	0/1	0/1	0/1	0/1	0/1
Chen 2020 (37)	1	0/1	1/1	1/1	0/1	0/1	0/1	0/1	0/1	0/1	1/1
Zeng 2020 (38)	1	1/1	0/1	0/1	0/1	0/1	0/1	0/1	0/1	0/1	0/1
Wang 2020 (40)	1	1/1	0/1	1/1	1/1	0/1	0/1	0/1	0/1	0/1	0/1
Quan 2020 (41)	1	1/1	0/1	0/1	0/1	0/1	0/1	0/1	0/1	0/1	0/1
Xiong 2020 (42)	2	2/2	0/2	2/2	2/2	2/2	0/2	0/2	0/2	0/2	1/2
Liu 2020 (46)	6	5/6	1/6	6/6	6/6	6/6	0/6	0/6	0/6	1/6	0/6
Zhao 2020 (49)	1	1/1	0/1	1/1	0/1	0/1	0/1	0/1	0/1	0/1	0/1
Zhang 2020 (52)	2	2/2	0/2	2/2	2/2	2/2	0/2	0/2	0/2	0/2	1/2
Liu 2020 (53)	1	1/1	0/1	1/1	0/1	0/1	0/1	0/1	0/1	0/1	1/1
Xiao 2020 (54)	1	1/1	0/1	1/1	1/1	1/1	0/1	0/1	0/1	0/1	0/1
Chan 2020 (56)	1	1/1	0/1	0/1	0/1	0/1	0/1	0/1	0/1	0/1	0/1
Kam 2020 (57)	1	1/1	0/1	1/1	0/1	0/1	0/1	0/1	0/1	0/1	0/1
Park 2020 (58)	1	1/1	0/1	1/1	0/1	0/1	1/1	0/1	0/1	0/1	0/1
Liu 2020 (60)	4	4/4	0/4	3/4	3/4	2/4	0/4	1/4	0/4	0/4	0/4
Wang 2020 (61)	1	1/1	0/1	0/1	0/1	0/1	0/1	0/1	0/1	0/1	0/1
Ji 2020 (63)	2	2/2	0/2	1/2	0/2	0/2	0/2	0/2	0/2	0/2	1/2
Xing 2020 (67)	3	3/3	0/3	3/3	0/3	0/3	0/3	0/3	0/3	0/3	0/3
Qian (71)	1	1/1	0/1	0/1	0/1	0/1	0/1	0/1	0/1	0/1	0/1
Sun (74)	8	0/8	8/8	6/8	6/8	4/8	4/8	1/8	0/8	8/8	3/8
Dong (75)	2	2/2	0/2	1/2	1/2	1/2	1/2	0/2	0/2	0/2	0/2
Le (78)	1	1/1	0/1	0/1	0/1	0/1	0/1	0/1	0/1	0/1	0/1
Tang (81)	1	1/1	0/1	0/1	0/1	0/1	0/1	0/1	0/1	0/1	0/1

continue

Study ID	Headache	Nasal obstruction	Rhinorrhoea	Nausea or vomiting	No Symptom	More than one sign or symptom
Deng 2020 (33)	0/2	0/2	0/2	0/2	0/2	0/2
Cai 2020 (34)	0/1	0/1	0/1	1/1	0/1	1/1
Zhang 2020 (35)	0/1	0/1	0/1	0/1	0/1	0/1
Chen 2020 (37)	0/1	0/1	0/1	1/1	0/1	1/1
Zeng 2020 (38)	0/1	0/1	0/1	0/1	0/1	1/1
Wang 2020 (40)	0/1	0/1	0/1	1/1	0/1	1/1
Quan 2020 (41)	0/1	0/1	0/1	0/1	1/1	0/1
Xiong 2020 (42)	0/2	0/2	1/2	0/2	0/2	2/2
Liu 2020 (46)	0/6	0/6	1/6	4/6	0/6	6/6
Zhao 2020 (49)	0/1	0/1	0/1	0/1	0/1	0/1
Zhang 2020 (52)	0/2	0/2	0/2	0/2	0/2	2/2
Liu 2020 (53)	0/1	0/1	0/1	1/1	0/1	1/1
Xiao 2020 (54)	0/1	0/1	1/1	0/1	0/1	1/1
Chan 2020 (56)	0/1	0/1	0/1	0/1	1/1	0/1
Kam 2020 (57)	0/1	0/1	0/1	0/1	0/1	0/1
Park 2020 (58)	0/1	0/1	0/1	0/1	0/1	1/1
Liu 2020 (60)	0/4	0/4	0/4	0/4	0/4	2/4
Wang 2020 (61)	0/1	0/1	0/1	0/1	1/1	0/1
Ji 2020 (63)	0/2	0/2	0/2	0/2	0/2	0/2
Xing 2020 (67)	0/3	0/3	0/3	0/3	0/3	0/3
Qian (71)	0/1	0/1	0/1	0/1	1/1	0/1
Sun (74)	1/8	0/8	0/8	4/8	0/8	8/8
Dong (75)	0/2	0/2	0/2	0/2	0/2	1/2
Le (78)	0/1	1/1	1/1	0/1	0/1	1/1
Tang (81)	0/1	0/1	0/1	0/1	1/1	0/1

Table B. Imaging findings and Family contact

Study ID	Number	Abnormal	Unilateral pneumonia	Bilateral pneumonia	Ground-glass opacity	Family contact
Deng 2020 (33)	2	0/2	0/2	0/2	0/2	2/2
Cai 2020 (34)	1	1/1	NR/1	NR/1	NR/1	1/1
Zhang 2020 (35)	1	1/1	NR/1	NR/1	NR/1	NR/1
Chen 2020 (37)	1	1/1	1/1	0/1	1/1	0/1
Zeng 2020 (38)	1	1/1	0/1	1/1	0/1	1/1
Wang 2020 (40)	1	1/1	1/1	0/1	1/1	1/1
Quan 2020 (41)	1	1/1	1/1	0/1	0/1	1/1
Xiong 2020 (42)	2	2/2	2/2	0/2	1/2	2/2
Liu 2020 (46)	6	4/5	0/5	4/5	1/5	0/6
Zhao 2020 (49)	1	1/1	1/1	0/1	0/1	1/1
Zhang 2020 (52)	2	1/2	0/2	1/2	NR/2	2/2
Liu 2020 (53)	1	1/1	0/1	1/1	1/1	1/1
Xiao 2020 (54)	1	1/1	0/1	1/1	0/1	1/1
Chan 2020 (56)	1	1/1	NR/1	NR/1	1/1	1/1
Kam 2020 (57)	1	NR/1	NR/1	NR/1	NR/1	1/1
Park 2020 (58)	1	1/1	1/1	0/1	1/1	1/1
Liu 2020 (60)	4	3/4	NR/4	NR/4	1/4	NR/4
Wang 2020 (61)	1	1/1	NR/1	NR/1	NR/1	1/1
Ji 2020 (63)	2	0/2	0/2	0/2	0/2	2/2
Xing 2020 (67)	3	2/3	2/3	0/3	2/3	3/3
Qian (71)	1	NR/1	NR/1	NR/1	NR/1	1/1
Sun (74)	8	8/8	2/8	6/8	6/8	5/8
Dong (75)	2	1/2	0/2	1/2	NR/2	NR/2
Le (78)	1	0/1	0/1	0/1	0/1	1/1
Tang (81)	1	0/1	0/1	0/1	0/1	0/1

NR: not report

Table C. Laboratory results

Study ID	Number	Leucocytes (× 10°/L)	Lymphocytes (× 10 ⁹ /L)	Neutrophils (× 10 ⁹ /L)	Platelets (× 10 ⁹ /L)	Haemoglobin (g/L)
Deng 2020 (33)	2	4.83/5.08	3.37/2.89	NR	225/287	NR
Cai 2020 (34)	1	16.0	NR	NR	138	NR
Zhang 2020 (35)	1	9.68	NR	NR	494	113
Chen 2020 (37)	1	7.52	NR	NR	183	108
Zeng 2020 (38)	1	7.66	NR	NR	399	132
Wang 2020 (40)	1	16.09	1.38	13.97	278	NR
Quan 202 0(41)	1	9.1	4.5	NR	234	138
Xiong 2020 (42)	2	6.0/6.2	2.56/3.73	2.18/1.72	301/252	112/117
Liu 2020 (46)	6	2.96/6.49/5.48/3.04 /3.95/1.8	1/1.19/1.25/1.7/0.87/0.36	1.3/3.15/2.54/0.66/2.85/0.27	203/272/256/191/153/165	104/120/113/118/115/120
Zhao 2020 (49)	1	3.9	NR	NR	NR	NR
Zhang 2020 (52)	2	5.94/8.98	NR	NR	255/324	111/112
Liu 2020 (53)	1	3.78	1.86	1.68	149	138
Xiao 2020 (54)	1	Normal	Normal	Normal	Normal	Normal
Chan 2020 (56)	1	6.5	2.8	3.2	197	146
Kam 2020 (57)	1	Normal	Normal	Normal	Normal	Normal
Park 2020 (58)	1	4.08	NR	NR	251	135
Liu 2020 (60)	4	Decreased/Normal/Normal/N ormal	Increased/Increased/Normal/Normal	NR	NR	NR
Wang 2020 (61)	1	NR	2.43	NR	NR	NR
Ji 2020 (63)	2	11.82/6.6	NR	NR	NR	NR
Xing 2020 (67)	3	7.3/9.6/6.0	5.4 /5.2 /4.9	1.2 /3.6/1.7	333.0 /411.0/186.0	332.0/359.0/332.0
Qian (71)	1	NR	NR	NR	NR	NR
Sun (74)	8	1.65/14.95/9.19/8.32/8.8/10.6 /3.85/7.6	0.69/1.96/2.7/6.41/3.6/4.04/1.7/2. 8	0.78/11.63/5.7/1.27/3.5/5.9/1. 9/3.8	140/68/145/666/247/515/154/25 0	83/90/103/111/123/150/159 /136
Dong (75)	2	NR/normal	NR/normal	NR/normal	NR/normal	NR/normal
Le (78)	1	10.23	8.3	1.19	230	112
Tang (81)	1	NR	NR	NR	NR	NR

continue

Study ID	Albumin (g/L)	Alanine aminotransferase (U/L)	Aspartate aminotransferase (U/L)	Total bilirubin (μmol/L)	Blood urea nitrogen (mmol/L)	Creatinine (µmol/L)
Deng 2020 (33)	NR	10.63/12.25	23.32/20.87	NR	NR	27.33/35.29
Cai 2020 (34)	NR	17	33	NR	NR	29
Zhang 2020 (35)	NR	NR	NR	NR	NR	NR
Chen 2020 (37)	Normal	Normal	Normal	Normal	15.9	224
Zeng 2020 (38)	Normal	Normal	Normal	Normal	Normal	Normal
Wang 2020 (40)	Normal	20	31	Normal	Normal	Normal
Quan 2020 (41)	Normal	Normal	Normal	Normal	Normal	Normal
Xiong 2020 (42)	43.2/Normal	58.5/Normal	83.5/Normal	NR/Normal	Normal	Normal
Liu 2020 (46)	40/45.2/43.6/45.4/44.3/4 2.3	6/14/11/23/43/15	45/30/42/64/36/37	NR/4/4.2/2.7/3.6/5.4	NR	33/34/22/29/23/30
Zhao 2020 (49)	Normal	Normal	Normal	Normal	496	Normal
Zhang 2020 (52)	NR/NR	12.48/13.11	45.48/63.94	NR	5.16/5.30	21.6/17.90
Liu 2020 (53)	NR	NR	NR	NR	NR	NR
Xiao 2020 (54)	Normal	Normal	Normal	Normal	Normal	Normal
Chan 2020 (56)	49.1	23.9	28.2	3.6	5.6	51
Kam 2020 (57)	NR	NR	NR	NR	NR	NR
Park 2020 (58)	NR	NR	NR	NR	NR	NR
Liu 2020 (60)	NR	NR	NR	NR	NR	NR
Wang 2020 (61)	NR	NR	143	33	NR	NR
Ji 2020 (63)	NR	NR	NR	NR	NR	NR
Xing 2020 (67)	NR	NR	NR	NR	NR	22.8/28.3/53.4
Qian (71)	NR	NR	NR	NR	NR	NR
Sun (74)	NR	58/66/36/100/55/9/16 /8	37/27/33/41/16/14/14/1 6	11.8/20.4/16.5/12.4/5.3/7. 8/8.1/8.1	NR	27.1/43.4/21.3/15/ 24.8/64.5/58/72.1
Dong (75)	NR/normal	NR/normal	NR/normal	NR/normal	NR/normal	NR/normal
Le (78)	NR	34.8	59.9	NR	NR	36.5
Tang (81)	NR	NR	NR	NR	NR	NR

continue

Study ID	Creatine kinase (U/L)	Lactate dehydrogenase (U/L)	Myoglobin (ug/L)	Procalcitonin (ng/mL)	CRP (mg/L)	Activated partial thromboplastin time (s)	Prothrombin time (s)	D-dimer (mg/L)
Deng 2020 (33)	75.33/83.78	NR	NR	0.19/<0.05	12/<10	Normal/NR	Normal/NR	0.41/NR
Cai 2020 (34)	NR	NR	NR	0.07	15	Normal	Normal	0.58
Zhang 2020 (35)	NR	NR	NR	0.073	5.66	NR	NR	NR
Chen 2020 (37)	NR	NR	NR	NR	NR	NR	14.3	Normal
Zeng 2020 (38)	NR	NR	NR	0.08	< 0.75	NR	NR	NR
Wang 2020 (40)	NR	NR	NR	NR	NR	Normal	Normal	Normal
Quan 2020 (41)	Normal	Normal	Normal	NR	< 0.499	NR	NR	NR
Xiong 2020 (42)	NR/Normal	NR	NR	NR/0.05	0.36/7.81	Normal	Normal	Normal
Liu 2020 (46)	29/50/77/148/71/82	384/197/476/375/297/ 280	NR	NR	38.4/21/23.32/11. 8/58.79/6.84	NA/32.2/43.7/41/34/41. 5	NR/13.2/12.8/11. 9/12.3/12.5	0.59/0.22/0.78/0.22/ 0.74/0.38
Zhao 2020 (49)	Normal	Normal	Normal	0.06	Normal	NR	NR	NR
Zhang 2020 (52)	30.48/102.53	318.37/540.33	NR	0.85/0.23	0.05/0.04	Normal	Normal	Normal
Liu 2020 (53)	NR	NR	NR	NR	NR	NR	NR	NR
Xiao 2020 (54)	Normal	Normal	Normal	Normal	Normal	Normal	Normal	Normal
Chan 2020 (56)	78	194	NR	NR	0.2	34.0	13.1	NR
Kam 2020 (57)	NR	NR	NR	NR	NR	NR	NR	NR
Park 2020 (58)	NR	NR	NR	NR	< 0.04	NR	NR	NR
Liu 2020 (60)	NR	NR	NR	NR	Normal/Normal/N ormal/Increased	NR	NR	NR
Wang 2020 (61)	479	NR	NR	NR	NR	NR	NR	NR
Ji 2020 (63)	NR	NR	NR	NR	34.64/3.49	NR	NR	NR
Xing 2020 (67)	73.2/88.6/91.0	264.3/NR/194.0	NR	0.23/0.21/0.73	<0.8/<5.0/10.5	NR	NR	860.0/230.0/190.0
Qian (71)	NR	NR	NR	NR	NR	NR	NR	NR
Sun (74)	15/20,702/33/148/2 62/106/72/77	394/888/282/891/471/ 370/209/187	NR	0.18/17.16/0.05/0.08/ 0.11/0.04/0.09/0.05	6.48/57.9/103/0.7 5/27.02/1/9.9/0.5	NR	NR	0.47/40.34/3.07/NR/ NR/NR/0.23/0.44
Dong (75)	NR/normal	NR/normal	NR/normal	NR/normal	NR/normal	NR/normal	NR/normal	NR/normal
Le (78)	NR	327	NR	0.08	0.32	NR	NR	NR
Tang (81)	NR	NR	NR	NR	NR	NR	NR	NR

NR: not report; NA: not applicable

Tables

Table 1. Characteristics of included studies

		Number					
First author	Study Location	All	M	F	- Age (year)	Study design	
Deng 2020 (33)	Xian	2	1	1	8.0±7.1	case report	
Cai 2020 (34)	Shanghai	1	1	0	7	case report	
Zhang 2020 (35)	Hunan	1	0	1	0.2 (0.1, 0.3)	case report	
Wei 2020 (36)	Hubei	9	2	7	0.58 (0.28, 0.79)	case series	
Chen 2020 (37)	Hubei	1	1	0	1.1	case report	
Zeng 2020 (38)	Hubei	1	1	0	0	case report	
Feng 2020 (39)	Shenzhen	15	5	10	8.0 ± 2.9	case series	
Wang 2020 (40)	Hubei	1	1	0	5.6	case report	
Quan 2020 (41)	Liaoning	1	0	1	4	case report	
Xiong 2020 (42)	Chongqing	2	1	1	5.2/5.2	case report	
Cai 2020 (43)	Shanghai	10	4	6	6.5 (4.0, 9.0)	case series	
Wang 2020 (44)	Xian	31	15	16	7.9 ± 4.0	case series	
Tang 2020 (45)	Shenzhen	26	9	17	6.90 ± 0.70	case series	
Liu 2020 (46)	Hubei	6	2	4	3.0 (3.0, 4.0)	case report	
Lu 2020 (47)	Hubei	171	104	67	7.1 ± 2.8	case series	
Ma 2020 (48)	Hubei	50	28	22	2.5 (0.9, 7.0)	case series	
Zhao 2020 (49)	Zhejiang	1	1	0	13	case report	
Li 2020 (50)	Hubei	30	18	12	6.5±3.4	case series	
Zhang 2020 (51)	Shandong	10	3	7	5.7±4.2	case series	
Zhang 2020 (52)	Hunan	2	0	2	1.2/1.2	case report	
Liu 2020 (53)	Hubei	1	1	0	9	case report	
Xiao 2020 (54)	Chongqing	1	0	1	7.83	case report	
Xu 2020 (55)	Chongqing	32	17	15	9.0 ± 4.7	case series	
Chan 2020 (56)	Hong Kong	1	1	0	10	case report	
Kam 2020 (57)	Singapore	1	1	0	0.5	case report	
Park 2020 (58)	Korea	1	0	1	10	case report	
Du 2020 (59)	Shandong	14	6	8	7.1 ± 4.7	case series	
Liu 2020 (60)	Shanghai	4	2	2	3.8±4.1	case report	
Wang 2020 (61)	Hubei	1	1	0	0	case report	
Rahimzadeh 2020 (62)	Iranian	9	6	3	5.0 (3.5, 5.5)	case series	
Ji 2020 (63)	Beijing	2	2	0	9/15	case report	
Xu 2020 (64)	Guangzhou	10	6	4	6.6 (1.8, 13.7)	case series	
Xia 2020 (65)	Hubei	20	13	7	4.7 ± 3.9	case series	
Dong 2020 (66)	Shanghai	731	420	311	10 (NR)	case series	
Xing 2020 (67)	Hong Kong	3	2	1	1.5/2.5/3.6	case report	
Yu 2020 (68)	Hubei	82	51	31	NR (0-16)	case series	
Liu 2020 (69)	Hubei	91	56	35	NA	case series	
Ma 2020 (70)	Hubei	115	73	42	NA	case series	
Qian 2020 (71)	Zhejiang	2	0	2	1.1	case report	
Qiu 2020 (72)	Zhejiang	36	23	13	8.3±3.5	cohort study	
Zhang 2020 (73)	Hubei	25	14	11	3.0 (2.0, 9.0).	case series	
Sun 2020 (74)	Hubei	8	6	2	5.0 (1.0, 13.7)	case report	

Dong 2020 (75)	Hubei	2	2	0	3/2.3	case report
Wu 2020 (76)	Shandong	74	44	30	6.0 (0.1, 15.1)	case series
Su 2020 (77)	Shandong	9	3	6	3.6 (1.8, 6.8)	case series
Le 2020 (78)	Vietnam	1	0	1	0.3	case report
Zhong 2020 (79)	Hunan	9	4	5	8 (1.5, 10.0)	case series
Yang 2020 (80)	Shandong	10	3	7	4 (2, 8)	case series
Tang 2020 (81)	Zhejiang	1	1	0	10	case report

Ages were reported either as mean \pm standard deviation, or median (interquartile range), or single year. NR: not report; NA: not applicable.

Table 2. Symptoms and imaging results of patients with COVID-19

The overall symptoms	ES	I^2	<i>P</i> -value
No Symptom	19% (14%, 23%)	70.7%	< 0.10
Mild symptom	94% (90%, 98%)	89.9%	< 0.10
Severe symptom	3% (2%, 4%)	22.5%	0.24
More than one sign or symptom	35% (21%, 48%)	80.8%	< 0.10
Specific symptoms			
Fever	48% (39%, 56%)	85.7%	< 0.10
Cough	39% (30%, 48%)	84.4%	< 0.10
Fever and Cough	30% (18%, 42%)	67.4%	< 0.10
Sputum production	19% (0%, 44%)	97.5%	< 0.10
Rhinorrhoea	9% (6%, 12%)	0.0%	0.79
Shortness of breath / Dyspnoea	9% (0%, 19%)	91.8%	< 0.10
Myalgia or fatigue	8% (5%, 12%)	56.7%	< 0.10
Diarrhoea	7% (5%, 9%)	0.0%	0.62
Nausea or vomiting	6% (4%, 9%)	0.0%	1.00
Nasal obstruction	6% (3%, 9%)	0.0%	0.59
Sore throat	6% (2%, 10%)	35.2%	0.13
Headache	4% (1%, 6%)	0.0%	0.61
Imaging findings			
Abnormal	66% (55%, 77%)	89.6%	< 0.10
Unilateral pneumonia	31% (20%, 43%)	81.5%	< 0.10
Bilateral pneumonia	28% (20%, 36%)	81.3%	< 0.10
Ground-glass opacity	35% (26%, 44%)	84.7%	< 0.10

Table 3. Laboratory results of children with COVID-19

Routine blood values	ES	I^2	<i>P</i> -value
Leucocytes (× 10°/L)	6.25 (5.97, 6.54)	0.0%	0.69
Above normal range	15% (4%, 26%)	77.3%	< 0.10
Below normal range	28% (17%, 38%)	85.4%	<0.10
Lymphocytes (× 10°/L)	2.84 (2.55, 3.13)	77.8%	<0.10
Above normal range	41% (2%, 80%)	98.5%	<0.10
Below normal range	15% (8%, 22%)	79.9%	< 0.10
Neutrophils (× 10°/L)	2.70 (2.10, 3.31)	93.8%	< 0.10
Above normal range	23% (0%, 48%)	85.8%	< 0.10
Below normal range	24% (4%, 44%)	58.5%	< 0.10
Platelets (× 10 ⁹ /L)	264.65 (254.17, 275.12)	91.2%	< 0.10
Above normal range	10% (3%, 17%)	45.5%	0.14
Below normal range	6% (0%, 16%)	80.6%	< 0.10
Haemoglobin (g/L)	127.21 (123.38, 131.04)	97.4%	< 0.10
Above normal range	13% (4%, 22%)	58.4%	< 0.10
Below normal range	5% (0%, 11%)	38.5%	0.20
Blood biochemistry			
Albumin (g/L)	45.30 (45.13, 45.47)	0.0%	0.70
Below normal range	35% (25%, 45%)	0.0%	0.33
Alanine aminotransferase (U/L)	20.46 (14.51, 26.41)	96.9%	< 0.10
Above normal range	11% (8%, 14%)	0.0%	0.72
Aspartate aminotransferase (U/L)	32.04 (30.25, 33.83)	49.2%	< 0.10
Above normal range	15% (9%, 21%)	45.8%	< 0.10
Total bilirubin (μmol/L)	8.14 (1.45, 14.82)	97.5%	< 0.10
Above normal range	3% (0%, 6%)	NA	NA
Blood urea nitrogen (mmol/L)	3.81 (3.43, 4.18)	0.0%	0.56
Above normal range	12% (0%, 33%)	94.9%	< 0.10
Below normal range	14% (0%, 35%)	57.6%	0.13
Creatinine (µmol/L)	41.60 (32.98, 50.22)	95.6%	< 0.10
Above normal range	12% (0%, 33%)	94.9%	< 0.10
Below normal range	8% (3%, 14%)	0.0%	0.59
Creatine kinase (U/L)	104.37 (95.66, 113.08)	56.6%	0.10
Above normal range	13% (0%, 38%)	77.0%	< 0.10
Lactate dehydrogenase (U/L)	264.43 (241.85, 287.02)	98.1%	< 0.10
Above normal range	38% (25%, 51%)	72.9%	< 0.10
Below normal range	11% (0%, 32%)	NA	NA
Myoglobin (ug/L)	15.33 (11.18, 19.48)	NA	NA
Procalcitonin (g/L)	0.06 (0.00, 0.16)	0.0%	1.00
Above normal range	44% (20%, 69%)	98.0%	< 0.10
CRP (mg/L)	5.05(1.86, 8.24)	86.9%	< 0.10
Above normal range	22% (15%, 28%)	71.3%	<0.10
Coagulation function			
Activated partial thromboplastin time (s)	37.59 (28.69, 46.48)	96.4%	< 0.10
Increased	11% (5%, 18%)	0.0%	0.72
Decreased	4% (0%, 8%)	NA	NA
Prothrombin time (s)	12.25 (11.30, 13.20)	99.0%	< 0.10

		-	
1	п		

Increased	2% (0%, 4%)	0.0%	0.42
Decreased	2% (0%, 6%)	NA	NA
D-dimer (mg/L)	0.33 (0.17, 0.49)	0.0%	0.98
Increased	15% (7%, 22%)	38.4%	0.17

NA: not applicable

Figure




Figure 1. Flow diagram